Recent News

• 09.11.2025 - Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
• 09.09.2025 - Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
• 08.18.2025 - Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
• 08.18.2025 - Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
• 08.14.2025 - Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
• 08.14.2025 - Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
• 07.28.2025 - Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

Recent Filings

• 09.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.09.2025 - EX-99.1 EX-99.1
• 08.29.2025 - EX-99.1 EX-99.1
• 08.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.18.2025 - EX-99.1 EX-99.1
• 08.18.2025 - EX-99.1 EX-99.1
• 08.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]